Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$31.49
$31.43
$19.05
▼
$32.56
$3.86B0.742.62 million shsN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$44.58
+2.4%		$39.54
$12.30
▼
$48.40
$4.73B0.31.15 million shs2.02 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.63
+0.2%		$13.50
$5.69
▼
$13.63
$3.57B1.552.47 million shs1.46 million shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$24.43
-2.4%		$24.72
$18.80
▼
$27.66
$997.34M0.27672,401 shs728,683 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
0.00%0.00%+0.06%+1.09%+58.56%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
0.00%+13.24%-4.16%+25.93%+243.22%
Organon & Co. stock logo
OGN
Organon & Co.
0.00%+0.30%+0.59%+2.03%+47.45%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.00%-5.26%-1.81%+10.03%-0.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$31.49
$31.43
$19.05
▼
$32.56
$3.86B0.742.62 million shsN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$44.58
+2.4%		$39.54
$12.30
▼
$48.40
$4.73B0.31.15 million shs2.02 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.63
+0.2%		$13.50
$5.69
▼
$13.63
$3.57B1.552.47 million shs1.46 million shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$24.43
-2.4%		$24.72
$18.80
▼
$27.66
$997.34M0.27672,401 shs728,683 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
0.00%0.00%+0.06%+1.09%+58.56%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
0.00%+13.24%-4.16%+25.93%+243.22%
Organon & Co. stock logo
OGN
Organon & Co.
0.00%+0.30%+0.59%+2.03%+47.45%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.00%-5.26%-1.81%+10.03%-0.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
2.56
Moderate Buy$32.001.62% Upside
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.82
Moderate Buy$48.759.35% Upside
Organon & Co. stock logo
OGN
Organon & Co.
1.71
Reduce$11.40-16.36% Downside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.29
Hold$29.8021.98% Upside

Current Analyst Ratings Breakdown

Latest PCRX, EWTX, CPRX, and OGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$24.00 ➝ $25.00
8/5/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$32.00 ➝ $33.00
8/3/2026
Organon & Co. stock logo
OGN
Organon & Co.
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Hold (C-)
7/20/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$55.00
7/17/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/13/2026
Organon & Co. stock logo
OGN
Organon & Co.
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
7/9/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$51.00
7/6/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$41.00 ➝ $51.00
7/1/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$38.00
6/17/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$48.00 ➝ $59.00
6/17/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$20.00 ➝ $32.00
(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$596.96M6.46$2.92 per share10.77$7.76 per share4.06
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.93 per shareN/A
Organon & Co. stock logo
OGN
Organon & Co.
$6.22B0.58$5.80 per share2.35$2.89 per share4.72
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$726.41M1.34$3.76 per share6.49$16.11 per share1.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$214.33M$1.7418.1010.220.9637.08%35.76%31.31%N/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$167.79M-$1.85N/AN/AN/AN/A-39.01%-36.96%N/A
Organon & Co. stock logo
OGN
Organon & Co.
$187M$0.7717.703.961.263.41%88.97%6.03%N/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$7.03M$0.3569.809.01N/A1.96%9.68%5.30%N/A

Latest PCRX, EWTX, CPRX, and OGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.4677-$0.53-$0.0623-$0.53N/AN/A
8/4/2026Q2 2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.6460$0.73+$0.0840$0.12$191.06 million$192.40 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.59%N/A10.39%N/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A

Latest PCRX, EWTX, CPRX, and OGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/31/2026
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.59%8/14/20268/14/20269/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
7.10
6.84
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
16.24
16.24
Organon & Co. stock logo
OGN
Organon & Co.
8.43
1.95
1.44
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.54
5.04
3.94

Institutional Ownership

CompanyInstitutional Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%

Insider Ownership

CompanyInsider Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
10.40%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
21.30%
Organon & Co. stock logo
OGN
Organon & Co.
1.62%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80122.42 million109.69 millionOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
60108.60 million85.47 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
10,000262.61 million258.36 millionNot Optionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72039.86 million37.31 millionOptionable

Recent News About These Companies

Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?
August 10 at 9:36 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pacira-biosciences-pcrx-quietly-reframing-061005117.html
Hennion & Walsh Asset Management Inc. Buys 48,124 Shares of Pacira BioSciences, Inc. $PCRX
August 10 at 5:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hennion-walsh-asset-management-inc-buys-48124-shares-of-pacira-biosciences-inc-pcrx-2026-08-10/
Pacira BioSciences (NASDAQ:PCRX) Raised to "Strong-Buy" at Wall Street Zen
August 8 at 2:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947849
Pacira BioSciences (NASDAQ:PCRX) Upgraded by Wall Street Zen to Strong-Buy Rating
August 8 at 2:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacira-biosciences-nasdaqpcrx-upgraded-by-wall-street-zen-to-strong-buy-rating-2026-08-08/
Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform
August 8 at 1:23 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4933647-pacira-biosciences-reimbursement-is-turning-an-old-franchise-into-a-new-growth-platform
Needham & Company LLC Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) Stock
August 7 at 2:32 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30945681
Royal Bank Of Canada Increases Pacira BioSciences (NASDAQ:PCRX) Price Target to $25.00
August 7 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30945388
Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pacira-biosciences-pcrx-could-35-211402733.html
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in ...
August 6, 2026  |  caledonianrecord.comC
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pacira-biosciences-announces-publication-positive-120000262.html
Pacira BioSciences, Inc. $PCRX Shares Purchased by Pacer Advisors Inc.
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-pacira-biosciences-inc-pcrx-shares-purchased-by-pacer-advisors-inc-2026-08-06/
Pacira BioSciences (NASDAQ:PCRX) Reaches New 1-Year High on Better-Than-Expected Earnings
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943452
Pacira BioSciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931089-pacira-biosciences-inc-2026-q2-results-earnings-call-presentation
Pacira outlines $735M-$760M 2026 revenue guidance while targeting 160M EXPAREL covered lives
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4625552-pacira-outlines-735m-760m-2026-revenue-guidance-while-targeting-160m-exparel-covered-lives
Pacira Q2 earnings & revenues beat, 2026 sales outlook cut
August 5, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/pacira-q2-earnings-revenues-beat-2026-sales-outlook-cut/ar-AA29taO8
Pacira BioSciences (NASDAQ:PCRX) Trading Down 7.9% - Should You Sell?
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacira-biosciences-nasdaqpcrx-trading-down-79-should-you-sell-2026-08-05/
Royal Bank Of Canada Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) Stock
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/royal-bank-of-canada-forecasts-strong-price-appreciation-for-pacira-biosciences-nasdaqpcrx-stock-2026-08-05/
Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $33.00
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacira-biosciences-nasdaqpcrx-price-target-raised-to-3300-2026-08-05/
Pacira BioSciences Q2 Earnings Call Highlights
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacira-biosciences-q2-earnings-call-highlights-2026-08-04/
Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
August 4, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930387-pacira-biosciences-inc-pcrx-q2-2026-earnings-call-transcript
Pacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacira-biosciences-nasdaqpcrx-releases-quarterly-earnings-results-beats-estimates-by-008-eps-2026-08-04/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$31.49 0.00 (0.00%)
As of 07/16/2026

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$44.58 +1.06 (+2.44%)
As of 04:00 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$13.63 +0.03 (+0.22%)
As of 03:58 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$24.43 -0.59 (-2.36%)
As of 04:00 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas